Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/12088
Recommendations for measuring HIV reservoir size in cure-directed clinical trials.
Abdel-Mohsen, Mohamed | Richman, Douglas | Siliciano, Robert F | Nussenzweig, Michel C | Howell, Bonnie J | Martinez-Picado, Javier | Chomont, Nicolas | Bar, Katharine J | Yu, Xu G | Lichterfeld, Mathias | Alcamí, José ISCIII | Hazuda, Daria | Bushman, Frederic | Siliciano, Janet D | Betts, Michael R | Spivak, Adam M | Planelles, Vicente | Hahn, Beatrice H | Smith, Davey M | Ho, Ya-Chi | Gaebler, Christian | Paiardini, Mirko | Li, Qingsheng | Estes, Jacob D | Hope, Thomas J | Kostman, Jay | Mounzer, Karam | Caskey, Marina | Fox, Lawrence | Frank, Ian | Riley, James L | Tebas, Pablo | Montaner, Luis J | Buzon, Maria J
Nat Med . 2020 Sep;26(9):1339-1350.
Therapeutic strategies are being clinically tested either to eradicate latent HIV reservoirs or to achieve virologic control in the absence of antiretroviral therapy. Attaining this goal will require a consensus on how best to measure the numbers of persistently infected cells with the potential to cause viral rebound after antiretroviral-therapy cessation in assessing the results of cure-directed strategies in vivo. Current measurements assess various aspects of the HIV provirus and its functionality and produce divergent results. Here, we provide recommendations from the BEAT-HIV Martin Delaney Collaboratory on which viral measurements should be prioritized in HIV-cure-directed clinical trials.
HIV latency | HIV reservoirs | Viral measurements | HIV Cure | HIV persistence | Replication-competent HIV
Anti-Retroviral Agents | CD4-Positive T-Lymphocytes | Clinical Trials as Topic | Disease Reservoirs | HIV Infections | HIV-1 | Humans | Mass Screening | Viral Load | Virus Latency
Files in this item
- RecommendationsForMeasuringHIV ...